Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$466.9M
58M shares
52-week range
$6.50 – $9.35
59% from low
Exchange
NASDAQ
CS
P/S (TTM)
2.5
EV / FCF (TTM)
17.2
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
www.kamada.comNo one on the platform currently holds KMDA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 762,948 | $6.4M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-27 | $0.1700 | 2026-09-17 |
| 2026-03-23 | $0.2500 | 2026-04-07 |
| 2025-03-17 | $0.2000 | 2025-04-07 |
No one on the platform has traded KMDA yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.0% | — | — | — | ||
| Rev. Growth % | 12.1% | 6.3% | ||||
| Profit Margin % | 11.2% | 4.4% | 7.0% | |||
| Free Cash Flow Margin % | 9.4% | 7.6% | 7.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +10.5% on the P/E track.
At today's price, your expected annual return is +15.7% on the P/E track.
At today's price, your expected annual return is +20.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $204M | +12.3% | $0.49 | $0.46–$0.52 | 16.8× | 3 |
| 2027 | $226M | +11.2% | $0.60 | $0.52–$0.71 | 13.7× | 3 |
| 2028 | $246M | +8.5% | $0.68 | $0.67–$0.69 | 12.0× | 1 |
| 2029 | $266M | +8.4% | $0.77 | $0.75–$0.78 | 10.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.11 | $0.16 | +42.2% |
| 2026-05-13 | $0.12 | $0.07 | -41.7% |
| 2026-03-11 | $0.09 | $0.06 | -33.3% |
| 2025-11-10 | $0.10 | $0.09 | -10.0% |
| 2025-08-13 | $0.09 | $0.13 | +44.4% |
| 2025-05-14 | $0.07 | $0.07 | +0.0% |
| 2025-03-05 | $0.05 | $0.07 | +40.0% |
| 2024-11-13 | $0.07 |
| $0.07 |
| +0.0% |
| $4.2B |
| — |
| QSIQuantum-Si incorporated | $0.73 | +0.29% | $144M | — |
| RCKTRocket Pharmaceuticals, Inc. | $3.29 | -4.15% | $359M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$KMDA This one turned up on Equibles. Kamada Ltd director Tsur David reported selling 162,760 KMDA shares on September 8, 2026, worth about $1.34 million, in a non-derivative Form 4.
View on StockTwits ↗
New research today on @kamada $KMDA #sidotiresearch Read note: http://dlvr.it/TV45qD #investing #smallcap #microcap
View on StockTwits ↗
Wall St is expecting 0.13 EPS for $KMDA Q3 [Reporting 11/16 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$KMDA reported 0.17 EPS and 54.92 revenue for Q2. http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_content=KMDA&utm_
View on StockTwits ↗New research today on @kamada $KMDA #sidotiresearch Read note: http://dlvr.it/TTzk3T #investing #smallcap #microcap
View on StockTwits ↗
$KMDA has announced that CFO Chaime Orlev will step down effective December 31, 2026, to pursue other opportunities and will provide transitional support to the incoming CFO. The company has launched a search to identify a successor. https://biotuesdays.com/2026/08/12/kamada-transitions-cfo-launches-search-for-successor/
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-12-kamada-ltd-stock/ $KMDA Kamada Earnings Transcript
View on StockTwits ↗
$KMDA posted record-high H1 2026 results, double-digit revenue and EBITDA growth, and a $50M three-year plasma sales deal.
View on StockTwits ↗
$KMDA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.16 up 23.08% YoY • Reported revenue of $54.92M up 22.72% YoY • Kamada Ltd. is reiterating its 2026 annual financial guidance of total revenues in the range of $200 million to $205 million, and adjusted EBITDA in the range of $50 million to $53 million.
View on StockTwits ↗New research today on @kamada $KMDA #sidotiresearch Read note: http://dlvr.it/TTZvv6 #investing #smallcap #microcap
View on StockTwits ↗$KMDA highlighted ISHLT study results showing CYTOGAM improves outcomes in high-risk lung transplant patients.
View on StockTwits ↗
New research on @kamada $KMDA #sidotiresearch Read note: http://dlvr.it/TSvBs9 #investing #smallcap #microcap
View on StockTwits ↗Wall St is expecting 0.11 EPS for $KMDA Q2 [Reporting 08/19 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗New research today on @kamada $KMDA #sidotiresearch Read note: http://dlvr.it/TSWpzs #investing #smallcap #microcap
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.